Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
Chemodex
Diclofenac Impurity C
412
CHF
CHF 412.00
In stock
CDX-D1227-M05050 mgCHF 412.00
| Product Details | |
|---|---|
| Synonyms | Diclofenac impurity C (PhEur); o-(2,6-Dichloranilino)-benzylalkohol; (2-[(2,6-Dichlorophenyl)amino]phenyl)methanol |
| Product Type | Chemical |
| Properties | |
| Formula | C13H11Cl2NO |
| MW | 268.14 |
| CAS | 27204-57-5 |
| Source/Host Chemicals | Synthetic |
| Purity Chemicals | ≥98% (HPLC) |
| Appearance | White to off-white powder or crystals. |
| Solubility | Soluble in DMSO. |
| Identity | Determined by 1H-NMR. |
| Declaration | Manufactured by Chemodex. |
| Other Product Data |
Click here for Original Manufacturer Product Datasheet |
| InChi Key | HFLGAAAKRFLWLN-UHFFFAOYSA-N |
| Smiles | ClC1=C(NC2=CC=CC=C2CO)C(Cl)=CC=C1 |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice | Protect from light and moisture. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS | Inquire |
| Product Specification Sheet | |
| Datasheet |
 Download PDF |
Description
Diclofenac Impurity C is a degradation product of and a regulatory impurity in the drug Diclofenac which is a non-steroidal anti-inflammatory drug (NSAID) that is clinically used to treat inflammation associated with arthritis and gout as well as other pain or inflammatory disorders. This product can be used as a working standard or secondary analytical reference standard. It can also be used as an organic building block and intermediate for synthesis.
Product References
(1) C. Martinez, et al.; Appl. Cat. B Environ. 107, 110 (2011) | (2) X. Cheng, et al.; J. Environm. Chem. Eng. 3, 1713 (2015) | (3) M. Azougagh, et al.; Ann. Pharm. Fr. 74, 358 (2016) | (4) S. Orlandini, et al.; J. Chromatogr. A 1466, 189 (2016) | (5) C. Caprini, et al.; J. Pharm. Biomed. Anal. 149, 249 (2018) | (6) Y. Tateishi, et al.; ACS Omega 5, 32608 (2020)